Browsing Category
Pharma Industry News
4740 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Merck and Eisai announce major win as Welireg plus Lenvima delays progression in advanced renal cell carcinoma
Find out how Merck and Eisai’s Welireg + Lenvima combo redefines kidney cancer care after immunotherapy and what this major Phase 3 win means for investors.
The next frontier: Can CAR T therapy become a one-time cure for autoimmune diseases?
Can CAR T therapy move beyond cancer and offer one-time remission for autoimmune disease? A deep look at early data, industry shifts, and clinical implications.
Merck’s kidney cancer breakthrough hits one target—Will it be enough to change how doctors treat RCC?
Merck and Eisai’s new kidney cancer combination met a key Phase 3 goal. Discover what it means for patients, investors, and the oncology landscape.
Neumora (NASDAQ: NMRA) to begin Phase 1 trial of oral NLRP3 obesity pill in early 2026: Can it rival GLP-1 pills?
Find out how Neumora Therapeutics’ oral obesity candidate NMRA‑215 is advancing to human trials. Could it reshape the future of weight loss therapies?
Wellgistics Health partners with DataVault AI to launch blockchain-powered PharmacyChain platform for drug distribution transparency
Find out how Wellgistics Health and DataVault AI are transforming prescription-drug transparency with PharmacyChain, a blockchain smart-contract platform.
Intellia’s Nexiguran Ziclumeran (nex-z) phase 3 trials paused following grade 4 liver toxicity event
Find out why Intellia Therapeutics paused its phase 3 Nexiguran Ziclumeran (nex-z) trials after a severe liver event—and what it means for CRISPR’s future.
Avacta Group PLC (AIM: AVCT) shares rise on dual payload breakthrough: Is a clinical re-rating next?
Avacta shares rise after unveiling dual payload cancer therapy at AACR-NCI-EORTC. Can the stock sustain momentum as it approaches clinical milestones?
Can Sagimet turn denifanstat into a multi-indication platform and licensing engine beyond acne?
Can Sagimet parlay its acne win into a licensing engine and platform biotech story? Explore how FASN inhibition is being redefined across diseases.
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?
MapLight Therapeutics prices $250m Nasdaq IPO at $17 a share as biotech listings rebound
Find out how MapLight Therapeutics’ $250 million Nasdaq IPO is reigniting biotech investor sentiment and funding its next wave of CNS drug trials.